Last reviewed · How we verify
VI
VI is a varicella zoster virus vaccine that stimulates immune response to prevent herpes zoster (shingles) infection.
VI is a varicella zoster virus vaccine that stimulates immune response to prevent herpes zoster (shingles) infection. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults aged 18 years and older.
At a glance
| Generic name | VI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant zoster vaccine |
| Target | Varicella zoster virus glycoprotein E (gE) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
VI (Shingrix) is a recombinant zoster vaccine containing VZV glycoprotein E antigen combined with an AS01B adjuvant system. It works by priming both CD4+ and CD8+ T-cell responses against varicella zoster virus, providing durable protection against herpes zoster and post-herpetic neuralgia in older adults and immunocompromised populations.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of herpes zoster in immunocompromised adults aged 18 years and older
Common side effects
- Myalgia
- Fatigue
- Headache
- Injection site erythema
- Injection site swelling
- Fever
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (PHASE3)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
- Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE1, PHASE2)
- This Study Evaluates Skin Response Following Application of a Collagen-based Material in Healthy Adult Volunteers Using a Standardized Skin Prick Test. Skin Responses Will be Assessed at Multiple Time Points Following Application, and the Study is Intended to Evaluate Dermal Safety. (NA)
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Relationship Between Chronic Non-Specific Neck Pain And Lumbar Reposition Sense (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VI CI brief — competitive landscape report
- VI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI